LifeBridge Health   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Baltimore MD United States (1866)

Organization Overview

First Clinical Trial
2006
NCT00370045
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Department of Medicine, Sinai Hospital, Baltimore | LifeBridge Health | Sinai Hospital, Baltimore | Sinai Hospital of Baltimore | Sinai Hospital of Baltimore (Sinai Center for Thrombosis Research) | Sinai Hospital of Baltimore, The Alvin and Lois Lapidus Cancer Institute

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Angina, Stable (Phase 4)

Carcinoma, Ovarian Epithelial (Phase 2)

Cardiovascular Diseases (Phase 4)

Chronic Disease (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Endometrial Neoplasms (Phase 2)

Ethmoid Sinusitis (Phase 3)

Infarction (Phase 4)

Infections (Phase 1)

Inflammation (Phase 4)

Joint Diseases (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Nasal Polyps (Phase 3)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Ovarian Neoplasms (Phase 2)

Peripheral Arterial Disease (Phase 4)

Polyps (Phase 3)

Prosthesis-Related Infections (Phase 1)

Recurrence (Phase 2)

Sinusitis (Phase 3)

Sphenoid Sinusitis (Phase 3)

Vascular Diseases (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 29